Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Xencor Inc (XNCR)

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,016,261
  • Shares Outstanding, K 58,324
  • Annual Sales, $ 122,690 K
  • Annual Income, $ -69,330 K
  • 60-Month Beta 0.69
  • Price/Sales 15.89
  • Price/Cash Flow N/A
  • Price/Book 3.05
Trade XNCR with:

Options Overview

Details
  • Implied Volatility 67.89%
  • Historical Volatility 32.25%
  • IV Percentile 87%
  • IV Rank 78.02%
  • IV High 78.96% on 10/28/20
  • IV Low 28.58% on 08/05/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.75
  • Number of Estimates 4
  • High Estimate -0.60
  • Low Estimate -0.88
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -240.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.12 +14.77%
on 08/20/21
34.93 -1.03%
on 09/02/21
+2.12 (+6.53%)
since 08/17/21
3-Month
30.12 +14.77%
on 08/20/21
37.66 -8.20%
on 06/21/21
-2.47 (-6.67%)
since 06/17/21
52-Week
30.12 +14.77%
on 08/20/21
58.35 -40.75%
on 02/24/21
-7.55 (-17.92%)
since 09/17/20

Most Recent Stories

More News
Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

COMTEX_392115206/2669/2021-08-24T08:30:34

MOR : 12.00 (+0.17%)
XNCR : 34.57 (+3.44%)
INCY : 75.99 (+1.27%)
Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 34.57 (+3.44%)
Xencor: Q2 Earnings Snapshot

MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Wednesday reported second-quarter net income of $52.2 million, after reporting a loss in the same period a year earlier.

XNCR : 34.57 (+3.44%)
Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that...

XNCR : 34.57 (+3.44%)
MorphoSys AG Reports Second Quarter and First Half 2021 Results

XNCR : 34.57 (+3.44%)
MOR : 12.00 (+0.17%)
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that...

XNCR : 34.57 (+3.44%)
Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XNCR : 34.57 (+3.44%)
Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could...

XNCR : 34.57 (+3.44%)
Xencor Enters Oversold Territory (XNCR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

XNCR : 34.57 (+3.44%)
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study

Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.

CANF : 1.7400 (unch)
XNCR : 34.57 (+3.44%)
SVRA : 1.3900 (+8.59%)
ACER : 2.46 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 37.21
2nd Resistance Point 35.90
1st Resistance Point 35.24
Last Price 34.57
1st Support Level 33.27
2nd Support Level 31.96
3rd Support Level 31.30

See More

52-Week High 58.35
Fibonacci 61.8% 47.56
Fibonacci 50% 44.23
Fibonacci 38.2% 40.90
Last Price 34.57
52-Week Low 30.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar